

2-19-2020

## **Galcanezumab-Induced Anaphylaxis: A Case Report**

Erick Perez Sifontes

*HCA Healthcare*, Erick.PerezSifontes@hcahealthcare.com

Sonja Knittel-Hliddal

*HCA Healthcare*, Sonja.KnittelHliddal@hcahealthcare.com

Zhao Han

*HCA Healthcare*, Zhao.han@hcahealthcare.com

Rahimullah Asad

*HCA Healthcare*, Rahimullah.Asad@hcahealthcare.com

Aya Marachi

*HCA Healthcare*, Aya.Marachi@hcahealthcare.com

*See next page for additional authors*

Follow this and additional works at: <https://scholarlycommons.hcahealthcare.com/pulmonary>



Part of the [Pulmonology Commons](#)

---

### **Recommended Citation**

Perez Sifontes E, Knittel-Hliddal S, Han Z, et al. Galcanezumab-Induced Anaphylaxis: A Case Report. Presented at: Society for Critical Care Medicine; February 16-19, 2020; Orlando, FL.

This Presentation is brought to you for free and open access by the Research & Publications at Scholarly Commons. It has been accepted for inclusion in Pulmonary Disease by an authorized administrator of Scholarly Commons.

---

**Authors**

Erick Perez Sifontes, Sonja Knittel-Hliddal, Zhao Han, Rahimullah Asad, Aya Marachi, and Uma Iyer



UNIVERSITY OF  
CENTRAL FLORIDA



NORTH FLORIDA REGIONAL HEALTHCARE

UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE / HCA HEALTHCARE GME CONSORTIUM



Summary

Discussion

Case Report

Overview

# Galcanezumab induced anaphylaxis: a case report

Erick Perez Sifontes

PGY-2 Internal Medicine Residency Program

UCF College of Medicine /North Florida Regional Medical Center


# Monoclonal Antibodies & Anaphylaxis

Summary

Discussion

Case Report

Overview



- **Epinephrine**
  - First line treatment (NIAID, FAAN – 2006)
  - Adrenergic receptors affected by anaphylaxis (Simons et al. 2010)
  - In vivo B2 activation in basophils/mast cells (Kaliner et al. 1974)
- **Antihistamines**
- **Steroids**

Summary

Discussion

Case Report

Plasmapheresis

>15KD

Overview

Summary

Discussion

Case Report

- Humanized mAb, binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
- Preventive treatment of episodic or chronic migraine (FDA, 2018)
- Three multicenter, randomized, double-blind, placebo-controlled studies
- 240 mg SC loading dose, then 120 mg/month
- Side effects: site reactions, nasopharyngitis, and nausea

Overview

### 18h post intubation

- ✓ Hemodynamically stable
- ✓ Minimal sedation
- ✓ SBT passed
- ✓ Methylprednisolone 2mg/kg
- ✓ Albuterol/Ipratropium inh. q4h
- ✓ Famotidine 40mg IV BID

7:05pm

### 1h post extubation

- RR >30rpm / r
- Wheezing/Stridor
- Epinephrine 1mg/kg
- Same dose steroids
- Albuterol/ipratropium nebs.
- Racemic epinephrine nebs.

7:25pm

47F hx asthma, anaphylaxis.  
 CC: Shortness of breath,  
 generalized flushing,  
 throat an... 20min  
 after se... on of  
 G... ne... x2 SC

the...  
 nephr... 3  
 Albuterol

Emergenc...  
 28 rpm  
 or, decreased



## Summary

### DIFFERENTIAL

- Angioedema
- Asthma
- Urticaria
- Foreign body
- Pulmonary embolism
- Vocal chord dysfunction
- Panic attack
- Anxiety

~27 days


- Basiliximab
- Natalizumab
- Rituximab

## Discussion

## Case Report

## Overview





Summary

Discussion

Case Report

Overview